Raymond James Keeps Their Hold Rating on Aerie Pharma (AERI)

Raymond James analyst Elliot Wilbur maintained a Hold rating on Aerie Pharma (AERIResearch Report) today. The company’s shares closed last Monday at $15.71.

According to TipRanks.com, Wilbur is a 1-star analyst with an average return of -0.5% and a 47.4% success rate. Wilbur covers the Healthcare sector, focusing on stocks such as Amphastar Pharmaceuticals, Amneal Pharmaceuticals, and Flexion Therapeutics.

Aerie Pharma has an analyst consensus of Strong Buy, with a price target consensus of $26.00.

See today’s analyst top recommended stocks >>

Based on Aerie Pharma’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $20.08 million and GAAP net loss of $39.65 million. In comparison, last year the company earned revenue of $18.54 million and had a GAAP net loss of $49.4 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Aerie Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye. Its products include Rhopressa, Roclatan, AR-13503, and AR-1105. The company was founded by David L. Epstein, Casey C. Kopczynski, Thomas J. van Haarlem, and Eric J. Toone on June 22, 2005 and is headquartered in Durham, NC.